In vitro antimicrobial susceptibility of glycopeptide-resistant enterococci
- PMID: 7789096
- DOI: 10.1016/0732-8893(94)00113-b
In vitro antimicrobial susceptibility of glycopeptide-resistant enterococci
Abstract
The results of susceptibility testing of 48 phenotyped strains of glycopeptide antibiotic-resistant enterococci are reported. Minimum inhibitory and bactericidal concentrations (MICs and MBCs) were determined for 27 vanA, 17 vanB, and 4 vanC strains. Antibiotics exhibiting the greatest activity included novobiocin (MIC90 = 8 micrograms/ml and MBC90 = 32 micrograms/ml), ramoplanin (MIC90 = 2 micrograms/ml and MBC90 = 4 micrograms/ml), and the streptogramin RP59500 (MIC90 = 4 micrograms/ml and MBC90 = 32 micrograms/ml). These antibiotics warrant further investigation as potentially useful agents, either alone or in combination, for treating enterococcal infections.
Comment in
-
Activity of the quinupristin-dalfopristin combination (RP-59500; Synercid) tested against vancomycin-resistant Enterococcus species.Diagn Microbiol Infect Dis. 1996 Jan;24(1):59-60. doi: 10.1016/0732-8893(95)00149-2. Diagn Microbiol Infect Dis. 1996. PMID: 8988766 No abstract available.
Similar articles
-
Comparative in-vitro activities of RP59500 (quinupristin/dalfopristin), CL 329,998, CL 331,002, trovafloxacin, clinafloxacin, teicoplanin and vancomycin against Gram-positive bacteria.J Antimicrob Chemother. 1997 Mar;39(3):405-9. doi: 10.1093/jac/39.3.405. J Antimicrob Chemother. 1997. PMID: 9096191
-
In vitro activity of the combination of trovafloxacin and other antibiotics against enterococci.Diagn Microbiol Infect Dis. 1997 Dec;29(4):233-9. doi: 10.1016/s0732-8893(97)00161-2. Diagn Microbiol Infect Dis. 1997. PMID: 9458980
-
In vitro activity of RP 59500 (quinupristin/dalfopristin) and ramoplanin against vancomycin-resistant Enterococcus faecium.Microb Drug Resist. 1995 Winter;1(4):335-9. doi: 10.1089/mdr.1995.1.335. Microb Drug Resist. 1995. PMID: 9158806
-
Treatment of vancomycin-resistant enterococci, with a focus on quinupristin-dalfopristin.Pharmacotherapy. 1996 Jul-Aug;16(4):584-92. Pharmacotherapy. 1996. PMID: 8840364 Review.
-
Evaluation of in vitro activity of quinupristin/dalfopristin and comparator antimicrobial agents against worldwide clinical trial and other laboratory isolates.Am J Med. 1998 May 29;104(5A):34S-42S. doi: 10.1016/s0002-9343(98)00153-3. Am J Med. 1998. PMID: 9684656 Review.
Cited by
-
Bacteriological activity of trovafloxacin, a new quinolone, against respiratory tract pathogens.Eur J Clin Microbiol Infect Dis. 1998 Jun;17(6):405-12. doi: 10.1007/BF01691573. Eur J Clin Microbiol Infect Dis. 1998. PMID: 9758283 Review.
-
Glycopeptide resistance in gram-positive cocci: a review.Interdiscip Perspect Infect Dis. 2012;2012:781679. doi: 10.1155/2012/781679. Epub 2012 Jun 19. Interdiscip Perspect Infect Dis. 2012. PMID: 22778729 Free PMC article.
-
Quinupristin-dalfopristin.Drugs. 1996 Sep;52(3):406-15. doi: 10.2165/00003495-199652030-00006. Drugs. 1996. PMID: 8875130 Review.
-
Trovafloxacin.Drugs. 1997 Sep;54(3):435-45; discussion 446. doi: 10.2165/00003495-199754030-00006. Drugs. 1997. PMID: 9279505 Review.
-
Influence of erythromycin resistance, inoculum growth phase, and incubation time on assessment of the bactericidal activity of RP 59500 (quinupristin-dalfopristin) against vancomycin-resistant Enterococcus faecium.Antimicrob Agents Chemother. 1997 Dec;41(12):2749-53. doi: 10.1128/AAC.41.12.2749. Antimicrob Agents Chemother. 1997. PMID: 9420051 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical